Literature DB >> 26227901

Combining large number of weak biomarkers based on AUC.

Li Yan1, Lili Tian2, Song Liu1.   

Abstract

Combining multiple biomarkers to improve diagnosis and/or prognosis accuracy is a common practice in clinical medicine. Both parametric and non-parametric methods have been developed for finding the optimal linear combination of biomarkers to maximize the area under the receiver operating characteristic curve (AUC), primarily focusing on the setting with a small number of well-defined biomarkers. This problem becomes more challenging when the number of observations is not order of magnitude greater than the number of variables, especially when the involved biomarkers are relatively weak. Such settings are not uncommon in certain applied fields. The first aim of this paper is to empirically evaluate the performance of existing linear combination methods under such settings. The second aim is to propose a new combination method, namely, the pairwise approach, to maximize AUC. Our simulation studies demonstrated that the performance of several existing methods can become unsatisfactory as the number of markers becomes large, while the newly proposed pairwise method performs reasonably well. Furthermore, we apply all the combination methods to real datasets used for the development and validation of MammaPrint. The implication of our study for the design of optimal linear combination methods is discussed.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  ROC analysis, AUC, linear combination, empirical AUC

Mesh:

Substances:

Year:  2015        PMID: 26227901      PMCID: PMC5823017          DOI: 10.1002/sim.6600

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  22 in total

Review 1.  Biomarkers and surrogate end points--the challenge of statistical validation.

Authors:  Marc Buyse; Daniel J Sargent; Axel Grothey; Alastair Matheson; Aimery de Gramont
Journal:  Nat Rev Clin Oncol       Date:  2010-04-06       Impact factor: 66.675

2.  Optimal Combinations of Diagnostic Tests Based on AUC.

Authors:  Xin Huang; Gengsheng Qin; Yixin Fang
Journal:  Biometrics       Date:  2010-06-16       Impact factor: 2.571

3.  Confidence intervals for P(Y1>Y2) with normal outcomes in linear models.

Authors:  Lili Tian
Journal:  Stat Med       Date:  2008-09-20       Impact factor: 2.373

4.  Optimal linear combinations of multiple diagnostic biomarkers based on Youden index.

Authors:  Jingjing Yin; Lili Tian
Journal:  Stat Med       Date:  2013-12-06       Impact factor: 2.373

5.  Comparison of non-parametric confidence intervals for the area under the ROC curve of a continuous-scale diagnostic test.

Authors:  Lejla Hotilovac
Journal:  Stat Methods Med Res       Date:  2008-04       Impact factor: 3.021

6.  Confidence intervals for the receiver operating characteristic area in studies with small samples.

Authors:  N A Obuchowski; M L Lieber
Journal:  Acad Radiol       Date:  1998-08       Impact factor: 3.173

7.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

8.  Linear combinations of biomarkers to improve diagnostic accuracy with three ordinal diagnostic categories.

Authors:  Le Kang; Chengjie Xiong; Paul Crane; Lili Tian
Journal:  Stat Med       Date:  2012-08-03       Impact factor: 2.373

9.  Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.

Authors:  Marc Buyse; Sherene Loi; Laura van't Veer; Giuseppe Viale; Mauro Delorenzi; Annuska M Glas; Mahasti Saghatchian d'Assignies; Jonas Bergh; Rosette Lidereau; Paul Ellis; Adrian Harris; Jan Bogaerts; Patrick Therasse; Arno Floore; Mohamed Amakrane; Fanny Piette; Emiel Rutgers; Christos Sotiriou; Fatima Cardoso; Martine J Piccart
Journal:  J Natl Cancer Inst       Date:  2006-09-06       Impact factor: 13.506

10.  Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer.

Authors:  Jude M Mulligan; Laura A Hill; Steve Deharo; Gareth Irwin; David Boyle; Katherine E Keating; Olaide Y Raji; Fionnuala A McDyer; Eamonn O'Brien; Max Bylesjo; Jennifer E Quinn; Noralane M Lindor; Paul B Mullan; Colin R James; Steven M Walker; Peter Kerr; Jacqueline James; Timothy S Davison; Vitali Proutski; Manuel Salto-Tellez; Patrick G Johnston; Fergus J Couch; D Paul Harkin; Richard D Kennedy
Journal:  J Natl Cancer Inst       Date:  2014-01       Impact factor: 13.506

View more
  10 in total

1.  Clinical and Genetic Determinants of Cardiomyopathy Risk among Hematopoietic Cell Transplantation Survivors.

Authors:  Kasey J Leger; Kara Cushing-Haugen; John A Hansen; Wenhong Fan; Wendy M Leisenring; Paul J Martin; Lue Ping Zhao; Eric J Chow
Journal:  Biol Blood Marrow Transplant       Date:  2016-03-08       Impact factor: 5.742

2.  Potential clinical impact of multiparametric quantitative MR spectroscopy in neurological disorders: A review and analysis.

Authors:  Ivan I Kirov; Assaf Tal
Journal:  Magn Reson Med       Date:  2019-08-08       Impact factor: 4.668

3.  Confidence Interval Estimation of the Youden index and corresponding cut-point for a combination of biomarkers under normality.

Authors:  Kristopher Attwood; Lili Tian
Journal:  Commun Stat Theory Methods       Date:  2020-04-27       Impact factor: 0.863

4.  Circulating miRNAs as Diagnostic and Prognostic Biomarkers in High-Grade Gliomas.

Authors:  Jianing Wu; Abdulrahman Al-Zahrani; Ozal Beylerli; Rinat Sufianov; Rustam Talybov; Svetlana Meshcheryakova; Galina Sufianova; Ilgiz Gareev; Albert Sufianov
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

5.  Comment on 'Circulating cell-free miRNAs as biomarker for triple-negative breast cancer'-Methodological challenges in combining miRNAs as circulating biomarkers.

Authors:  P Verderio; S Bottelli; M Lecchi; M Plebani; M Gariboldi; S Pizzamiglio; C M Ciniselli
Journal:  Br J Cancer       Date:  2016-04-21       Impact factor: 7.640

6.  Developing miRNA signatures: a multivariate prospective.

Authors:  Paolo Verderio; Stefano Bottelli; Sara Pizzamiglio; Chiara Maura Ciniselli
Journal:  Br J Cancer       Date:  2016-06-28       Impact factor: 7.640

7.  Quasi-linear score for capturing heterogeneous structure in biomarkers.

Authors:  Katsuhiro Omae; Osamu Komori; Shinto Eguchi
Journal:  BMC Bioinformatics       Date:  2017-06-19       Impact factor: 3.169

8.  SUMO-Activating Enzyme Subunit 1 (SAE1) Is a Promising Diagnostic Cancer Metabolism Biomarker of Hepatocellular Carcinoma.

Authors:  Jiann Ruey Ong; Oluwaseun Adebayo Bamodu; Nguyen Viet Khang; Yen-Kuang Lin; Chi-Tai Yeh; Wei-Hwa Lee; Yih-Giun Cherng
Journal:  Cells       Date:  2021-01-17       Impact factor: 6.600

9.  Identification of Biomarkers for Osteosarcoma Based on Integration Strategy.

Authors:  Junjie Bao; Zhaona Song; Chunyu Song; Yahui Wang; Wan Li; Wei Mai; Qingyu Shi; Hongwei Yu; Linying Ni; Yishu Liu; Xiaolin Lu; Chuan He; Lina Chen; Guofan Qu
Journal:  Med Sci Monit       Date:  2020-03-16

10.  Potential Salivary mRNA Biomarkers for Early Detection of Oral Cancer.

Authors:  Su Young Oh; Sung-Min Kang; Soo Hyun Kang; Heon-Jin Lee; Tae-Geon Kwon; Jin-Wook Kim; Sung-Tak Lee; So-Young Choi; Su-Hyung Hong
Journal:  J Clin Med       Date:  2020-01-16       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.